{"id":390101,"date":"2021-02-19T00:00:00","date_gmt":"2021-02-19T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0004-2020-biopharma-multiple-sclerosis-disease-landscape-and-forecast-g7-2020\/"},"modified":"2026-03-31T10:43:55","modified_gmt":"2026-03-31T10:43:55","slug":"dlsfcg0004-2020-biopharma-multiple-sclerosis-disease-landscape-and-forecast-g7-2020","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0004-2020-biopharma-multiple-sclerosis-disease-landscape-and-forecast-g7-2020\/","title":{"rendered":"Multiple Sclerosis | Disease Landscape and Forecast | G7 | 2020"},"content":{"rendered":"<p>The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment algorithm. Novartis&#8217;s Kesimpta, Bristol Myers Squibb&#8217;s Zeposia, and an array of other new and emerging next-generation compounds will intensify competition in the saturated relapsing MS market. Meanwhile, Ocrevus continues to transform treatment in the underserved PP-MS population while several emerging agents, including Sanofi Genzyme&#8217;s tolebrutinib and Roche&#8217;s fenebrutinib, are in Phase III development for progressive forms of MS. Separately, the looming entry of oral generics\u2014and the recent U.S. entry of generics for dimethyl fumarate\u2014will introduce a new variable in this high-cost market as reimbursement authorities race to rein in healthcare costs. Understanding these intersecting forces will be key to the success of current and future players in this evolving market.<\/p>\n<p><strong>Questions Answered: <\/strong><\/p>\n<ul>\n<li>What is the commercial outlook for next-generation fumarates, S1P receptor modulators, and anti-CD20 monoclonal antibodies (MAbs) in the competitive relapsing MS space, and where will they fit into an evolving treatment algorithm?<\/li>\n<li>How will novel DMTs, including the emerging BTK inhibitors (e.g., evobrutinib), be incorporated in the treatment of relapsing MS?<\/li>\n<li>What impact will tolebrutinib, fenebrutinib, ibudilast, and masitinib have in the progressive MS markets?<\/li>\n<li>What clinical roles will entrenched platform injectables and mainstay orals play in the evolving MS treatment algorithm?<\/li>\n<li>How will generic competition shape the MS market?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/p>\n<p><strong>Primary research:<\/strong> 26 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other DRG research.<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed prevalence of MS by country, segmented by CIS, RR-MS, SP-MS, and PP-MS; drug-treated cases.<\/p>\n<p><strong>Emerging therapies:<\/strong> Phase II: 8 drugs; Phase III\/preregistration: 7 drugs.<\/p>\n<p><strong>Key companies:<\/strong> AB Science, Banner Life Sciences, Biogen, Bristol Myers Squibb, Janssen, Merck KGaA \/ EMD Serono, MediciNova, Mylan, Mapi Pharma, Novartis, Roche \/ Genentech, Sanofi Genzyme, Teva, TG Therapeutics.<\/p>\n<p><strong>Market forecast features: <\/strong>Patient-based market forecast extending through 2029, segmented by brands and generics \/ biosimilars.<\/p>\n<p><strong>Product Description:<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast <\/em>provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution Enhancement<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast <\/em>will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n","protected":false},"template":"","class_list":["post-390101","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-sclerosis","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390101\/revisions"}],"predecessor-version":[{"id":576448,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390101\/revisions\/576448"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}